Filing Details

Schedule 13D ------------------------------------------- OMB APPROVAL ------------------------------------------- OMB Number: Expires: Estimated average burden hours per form................... ------------------------------------------- UNITED STAES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. N/A)* ImmunoPrecise Antibodies Ltd. -------------------------------------------------------------------------------- (Name of Issuer) Common -------------------------------------------------------------------------------- (Title of Class of Securities) 45257F200 -------------------------------------------------------------------------------- (CUSIP Number) Christian C. Park Ingalls & Snyder, LLC 1325 Avenue of the Americas New York, NY 10019 (212) 269-7894 -------------------------------------------------------------------------------- (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) June 29, 2023 -------------------------------------------------------------------------------- (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement of Schedule 13G to report the acquisition which is the subject of the Schedule 13D, and is filing this schedule because of 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box [ ]. *The remainder of this cover page shall be filed out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). (Continued on following page(s))

CUSIP No. 45257F200 13D -------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Ingalls & Snyder, LLC -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ] (b) [ X] -------------------------------------------------------------------------------- 3 SEC USE ONLY -------------------------------------------------------------------------------- 4 SOURCE OF FUNDS* OO -------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) [ ] -------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION New York -------------------------------------------------------------------------------- NUMBER OF 7 SOLE VOTING POWER SHARES 0 BENEFICIALLY -------------------------------------------------------------- OWNED BY 8 SHARED VOTING POWER EACH 0 REPORTING -------------------------------------------------------------- PERSON 9 SOLE DISPOSITIVE POWER WITH 0 -------------------------------------------------------------- 10 SHARED DISPOSITIVE POWER 1,053,186 -------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,053,186 -------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* [ ] -------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 4.22% -------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON* IA -------------------------------------------------------------------------------- The Shares reported herein are not limited to, but include those of the personal accounts of William McHale, an advisor representative of the Reporting Person. All of the individuals are advisory clients of the Reporting Person. The following Items are amended and restated in their entirety: Item 1. Security and Issuer ImmunoPrecise Antibodies Ltd. Common Stock (the "Shares") 3204 4464 Markham Street Victoria, BC V8Z 7X8 Item 2. Identity and Background (a)Ingalls & Snyder, LLC The Reporting Person is a limited liability company organized under the laws of the State of New York. (b)Business address and principal office for the Reporting Person: (c)Present principal occupation or employment and the name, principal business and address where employment occurs. (d) During the last five years,the Reporting Person has not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors). (e) During the last five years the Reporting Person was not a party to a civil proceeding of a judicial or administrative body of competent jurisdiction, and is not subject to a judgment, decree or final order enjoining future violations of,or prohibiting or mandating activities subject to, federalor state securities laws or finding any violation with respect to such laws. (f)Citizenship: Item 3. Source and Amount of Funds or Other Consideration. Personal funds of Reporting Persons' advisory clients. Item 4. Purpose of Transaction The Reporting Person along with other shareholders are collectively proposing a change to the members of the issuers board of directors. The views of the informal group will be expressed through written and oral communications, and may result in a call for a shareholder meeting on the issue. While the Reporting Person is along under the filing threshold requirement, it is electing to file this Schedule D as it is a part of a group of shareholders who share a common goal of effecting a change to the board members. There are no formal written agreements with other shareholders to act as a group. Item 5. Interest in Securities of the Issuer (a) The Reporting Person is the beneficial owner of 1,053,186 shares which is equivalent to 4.22% of the outstanding shares of the issuer based on the total number of outstanding shares reported by the issuer on its most recent Form 10-Q. The Reporting Person has the sole power to dispose of or direct the disposition of 0 shares, shared power to dispose of or direct the disposition of 1,053,186 shares, and shared voting power of 1,053,186 shares. (d) Not applicable. (e) Item 6.Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer. None Item 7. Material to be Filed as Exhibits. None Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: July 7, 2023 /s/ Christian C. Park Christian C. Park